Please login to the form below

interferon beta-1a

This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.

Latest news

Synairgen’s SNG001 advances into phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral ... This pH neutral, inhaled interferon beta-1a
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme

placebo. SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation and has previously been tested in phase 2 trials in asthma. ... INF-beta is a naturally occurring protein that controls the
UK biotech Synairgen reveals promising early results for COVID-19 drug

SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation and has previously been tested in phase 2 trials in asthma. ... The results confirm our belief that interferon-beta, a widely known drug that
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace

Finally, Merck KGaA has donated a supply of its interferon beta-1a product Rebif – approved for multiple sclerosis - to France’s INSERM research organisation following a request for use in a
UK biotech Synairgen to begin COVID-19 trial of lead candidate

SNG001 (inhaled formulation of interferon-beta-1a), as concerns grow in the UK that COVID-19 cases could soar in the comings weeks. ... Interferon-beta (IFN-beta) is a naturally occurring protein that controls the body’s antiviral responses.

More from news
Approximately 1 fully matching, plus 56 partially matching documents found.

Latest Intelligence

Tackling a formidable foe

Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Senior Account Manager: Competitive

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Account Director – Creative Healthcare Communications: Competative

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Medical Editor: Competitive

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Mistrust in medical research: a patient perspective: The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease: Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients: We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...